Home Newsfeeds Needham Maintains Buy on Cardlytics, Lowers Price Target to $8

Needham Maintains Buy on Cardlytics, Lowers Price Target to $8

Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $14 to $8.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $14 to $8.

Potential Takeover In Works for Cardiovascular Treatment Focused Cytokinetics

By Vandana Singh

November 1, 1:38 PM

Cytokinetics Inc (NASDAQ: CYTK), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover options as it has garnered interest from at least one major pharmaceutical company in recent months.

CYTK

News

Semtech Corporation And Sierra Wireless Announce Termination Of The Waiting Period Under The HSR Act

By Benzinga Newsdesk

January 5, 5:17 PM

Semtech Corporation (NASDAQ:SMTC) (“Semtech”) and Sierra Wireless, Inc. (NASDAQ:SWIR) (TSX:SW) (“Sierra”) today announced the termination of the applicable waiting period under the

SMTC

Why This Analyst Has Turned Bearish On BlackLine

By Priya Nigam

July 18, 12:29 PM

While Blackline Inc’s (NASDAQ: BL) business and management team are strong, the company’s stock is currently trading at a premium to its horizontal software peers and seems to reflect all the potential good news as well as some potential M&A premium, according to BofA Securities.

Apple’s $3 Trillion Crown Slips As Disappointing Sales Take Toll

By Bibhu Pattnaik

August 5, 11:51 AM

Apple Inc's (NASDAQ: AAPL) market value has dipped below the once-historic milestone of $3 trillion, triggered by

AAPL

Needham Maintains Buy on Cardlytics, Lowers Price Target to $8

Related Posts

Potential Takeover In Works for Cardiovascular Treatment Focused Cytokinetics

Semtech Corporation And Sierra Wireless Announce Termination Of The Waiting Period Under The HSR Act

Why This Analyst Has Turned Bearish On BlackLine

Apple’s $3 Trillion Crown Slips As Disappointing Sales Take Toll